key: cord-0825441-i0n6m0n5
authors: Juneja, Kavita; Humeniuk, Rita; Porter, Danielle; Cao, Huyen; Feng, Joy
title: Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
date: 2021-03-18
journal: Antimicrob Agents Chemother
DOI: 10.1128/aac.00085-21
sha: 69c751eb42a7b3e3ef392c6f4e368726edd2b59b
doc_id: 825441
cord_uid: i0n6m0n5

In their editorial "Remdesivir for COVID-19: Why Not Dose Higher?"….

that remdesivir treatment resulted in a direct antiviral effect with suppression of viral replication in lung secretions (9) . Notably, recent evidence from monoclonal antibody studies shows that viral load in the upper respiratory tract detected by nasopharyngeal swabs may have limited ability to predict COVID-19 outcomes (10) .

The results of the WHO Solidarity study do not diminish the positive findings of these three pivotal phase 3 studies, nor do results from the Wang et al. study in China (11, 12) . The Solidarity study, large and ambitious in scope, was designed and powered to evaluate a broad clinical endpoint of mortality. However, it was not designed to evaluate subgroups or more nuanced endpoints, such as time to recovery and odds of clinical improvement, which are important outcomes for both patients and overburdened health care systems (13, 14) . The double-blind, placebo-controlled study conducted by Wang et al., although laudable in its design, lacked adequate power (underpowered at 58%) to draw meaningful conclusions, although the observed efficacy signal was consistent with the ACTT-1 findings among individuals with a symptom duration of .10 days (15) .

Although the favorable benefit-risk profile for the currently approved dose and duration of remdesivir treatment has been clearly established, we also recognize the acute need to further enhance patient outcomes. Additional clinical trials are ongoing and planned to evaluate remdesivir in combination with anti-inflammatory agents in subpopulations and in outpatient settings. We will continue to share emerging data with regulatory authorities and the scientific and medical communities as we work together to help address the needs of patients with this devastating disease around the world.

Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, SARS-CoV-2 replication inhibitor

Remdesivir for the treatment of Covid-19-final report

Remdesivir for 5 or 10 days in patients with severe Covid-19

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

MRC-Toxicology Unit COVID-19 Consortium. 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

Repurposed antiviral drugs for Covid-19-interim WHO Solidarity trial results

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

FDA approval of remdesivir-a step in the right direction

A large, simple trial leading to complex questions

Remdesivir for COVID-19: challenges of underpowered studies